Showing results (211-220 of 679) with videos related to

Sort By:
Pageof 68
Clinical Lymphoma, Myeloma & Leukemia|November 22, 2025
Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific AntibodiesBénédicte Piron, Laura Rodrigo, Benoît Tessoulin, et al.
Expert Review of Hematology|January 12, 2017
Deacetylase inhibitors: an advance in myeloma therapy?Jacob P Laubach, Jesus F San-Miguel, Vania Hungria, et al.
Blood|April 28, 2006
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cellsEmmanuelle Menoret, Patricia Gomez-Bougie, Alexandrine Geffroy-Luseau, et al.
Human Immunology|January 29, 2023
Computational and atomistic studies applied to the understanding of the structural and behavioral features of the immune checkpoint HLA-G molecule and geneCinthia C Alves, Thaís Arns, Maria L Oliveira, et al.
Scientific Reports|January 25, 2018
Magneto-active substrates for local mechanical stimulation of living cellsCécile M Bidan, Mario Fratzl, Alexis Coullomb, et al.
Ejhaem|July 18, 2022
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligiblePieter Sonneveld, María-Victoria Mateos, Adrian Alegre, et al.
The Lancet. Oncology|June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyPhilippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Blood|July 10, 2014
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balanceBenoît Tessoulin, Géraldine Descamps, Philippe Moreau, et al.
Blood|February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years laterAntonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 11, 2024
DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approachBastien Jamet, Hatem Necib, Thomas Carlier, et al.
Pageof 68